ACOG PRACTICE BULLETIN No. 186: Long-Acting Reversible Contraception: Implants and Intrauterine Devices

Obstetrics and Gynecology

Volumn 130, Issue 5, 2017, Pages E251-E269

  Espey, Eve ^a   Hofler, Lisa ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ETONOGESTREL; CONTRACEPTIVE AGENT; DRUG IMPLANT;

ACTINOMYCES; ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ASYMPTOMATIC DISEASE; BREAST FEEDING; DEVICE REMOVAL; ECTOPIC PREGNANCY; ELIGIBILITY; EMERGENCY CONTRACEPTION; EVIDENCE BASED PRACTICE; HUMAN; INFECTION PREVENTION; INTERVAL INSERTION; LONG-ACTING REVERSIBLE CONTRACEPTION; MEDICAL PROCEDURES; MENOPAUSE; MENSTRUAL CYCLE; NULLIPARA; PATIENT SELECTION; PELVIC INFLAMMATORY DISEASE; POSTABORTION INSERTION; POSTPARTUM INSERTION; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRIORITY JOURNAL; RISK REDUCTION; SCREENING; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CYTOLOGY; DRUG IMPLANT; FEMALE; INTRAUTERINE CONTRACEPTIVE DEVICE; PRACTICE GUIDELINE;

CONTRACEPTIVE AGENTS, FEMALE; DRUG IMPLANTS; FEMALE; HUMANS; INTRAUTERINE DEVICES;

EID: 85032642026     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000002400     Document Type: Article

References (151)

1. Hov GG, Skjeldestad FE, Hilstad T. Use of IUD and subsequent fertility-follow-up after participation in a randomized clinical trial. Contraception 2007;75:88-92. (Level II-3)
2. Andersson K, Batar I, Rybo G. Return to fertility after removal of a levonorgestrel-releasing intrauterine device and Nova-T. Contraception 1992;46:575-84. (Level I)
3. Clinical challenges of long-acting reversible contraceptive methods. Committee Opinion No. 672. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e69-77. (Level III)
4. Kavanaugh ML, Jerman J, Finer LB. Changes in use of long-acting reversible contraceptive methods among U.S. women, 2009-2012. Obstet Gynecol 2015;126:917-27. (Level II-3)
5. Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008-2011. N Engl J Med 2016;374:843-52. (Level II-3)
6. Peipert JF, Madden T, Allsworth JE, Secura GM. Preventing unintended pregnancies by providing no-cost contraception. Obstet Gynecol 2012;120:1291-7. (Level II-3)
7. Harper CC, Rocca CH, Thompson KM, Morfesis J, Goodman S, Darney PD, et al. Reductions in pregnancy rates in the USA with long-acting reversible contraception: a cluster randomised trial. Lancet 2015;386:562-8. (Level I)
8. Diedrich JT, Zhao Q, Madden T, Secura GM, Peipert JF. Three-year continuation of reversible contraception. Am J Obstet Gynecol 2015;213:662.e1-8. (Level II-3)
9. Ricketts S, Klingler G, Schwalberg R. Game change in Colorado: widespread use of long-acting reversible contraceptives and rapid decline in births among young, low-income women. Perspect Sex Reprod Health 2014;46:125-32. (Level II-3)
10. Secura GM, Madden T, McNicholas C, Mullersman J, Buckel CM, Zhao Q, et al. Provision of no-cost, long-acting contraception and teenage pregnancy [published erratum appears in N Engl J Med 2014;372:297]. N Engl J Med 2014;371:1316-23. (Level II-3)
11. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007. (Level II-2)
12. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404. (Level III)
13. Trussell J, Hassan F, Lowin J, Law A, Filonenko A. Achieving cost-neutrality with long-acting reversible contraceptive methods. Contraception 2015;91:49-56. (Cost-benefit)
14. Rivera R, Yacobson I, Grimes D. The mechanism of action of hormonal contraceptives and intrauterine contraceptive devices. Am J Obstet Gynecol 1999;181:1263-9. (Level III)
15. Ortiz ME, Croxatto HB. Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action. Contraception 2007;75:S16-30. (Level III)
16. Godfrey EM, Folger SG, Jeng G, Jamieson DJ, Curtis KM. Treatment of bleeding irregularities in women with copper-containing IUDs: a systematic review. Contraception 2013;87:549-66. (Systematic Review)
17. ® (levonorgestrel-releasing intrauterine system). Highlights of prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2017. Available at: https://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Retrieved August 23, 2017. (Level III)
18. ® (levonorgestrel-releasing intrauterine system). Highlights of prescribing information. Irvine (CA): Allergan USA, Inc.; 2017. Available at: https://www.allergan.com/assets/pdf/lilettashi_pi. Retrieved August 23, 2017. (Level III)
19. TM (levonorgestrel-releasing intrauterine system). Highlights of prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2016. Available at http://labeling.bayerhealthcare.com/html/products/pi/Kyleena_PI.pdf. Retrieved August 23, 2017. (Level III)
20. ® (levonorgestrel-releasing intrauterine system). Highlights of prescribing information. Whippany (NJ): Bayer HealthCare Pharmaceuticals Inc.; 2017. Available at http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Retrieved August 23, 2017. (Level III)
21. Apter D, Gemzell-Danielsson K, Hauck B, Rosen K, Zurth C. Pharmacokinetics of two low-dose levonorgestrel-releasing intrauterine systems and effects on ovulation rate and cervical function: pooled analyses of phase II and III studies. Fertil Steril 2014;101:1656,62.e1-4. (Level I)
22. Natavio MF, Taylor D, Lewis RA, Blumenthal P, Felix JC, Melamed A, et al. Temporal changes in cervical mucus after insertion of the levonorgestrel-releasing intrauterine system. Contraception 2013;87: 426-31. (Level II-3)
23. Lewis RA, Taylor D, Natavio MF, Melamed A, Felix J, Mishell D Jr. Effects of the levonorgestrel-releasing intrauterine system on cervical mucus quality and sperm penetrability. Contraception 2010;82:491-6. (Level II-2)
24. Nelson A, Apter D, Hauck B, Schmelter T, Rybowski S, Rosen K, et al. Two low-dose levonorgestrel intrauterine contraceptive systems: a randomized controlled trial [published erratum appears in Obstet Gynecol 2014; 123:1109]. Obstet Gynecol 2013;122:1205-13. (Level I)
25. Gemzell-Danielsson K, Schellschmidt I, Apter D. A randomized, phase II study describing the efficacy, bleeding profile, and safety of two low-dose levonorgestrel-releasing intrauterine contraceptive systems and Mirena. Fertil Steril 2012;97:616,22.e1-3. (Level I)
26. Vickery Z, Madden T, Zhao Q, Secura GM, Allsworth JE, Peipert JF. Weight change at 12 months in users of three progestin-only contraceptive methods. Contraception 2013;88:503-8. (Level II-3)
27. Modesto W, de Nazare Silva dos Santos P, Correia VM, Borges L, Bahamondes L. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use. Eur J Contracept Reprod Health Care 2015;20:57-63. (Level II-2)
28. Ilse JR, Greenberg HL, Bennett DD. Levonorgestrel-releasing intrauterine system and new-onset acne. Cutis 2008;82:158. (Level III)
29. Bahamondes MV, Monteiro I, Castro S, Espejo-Arce X, Bahamondes L. Prospective study of the forearm bone mineral density of long-term users of the levonorgestrel-releasing intrauterine system. Hum Reprod 2010;25:1158-64. (Level II-3)
30. Lopez LM, Chen M, Mullins Long S, Curtis KM, Helmerhorst FM. Steroidal contraceptives and bone fractures in women: evidence from observational studies. Cochrane Database of Systematic Reviews 2015, Issue 7. Art. No.: CD009849. DOI: 10.1002/14651858. CD009849.pub3. (Systematic Review)
31. Nilsson CG, Lahteenmaki PL, Luukkainen T. Ovarian function in amenorrheic and menstruating users of a levonorgestrel-releasing intrauterine device. Fertil Steril 1984;41:52-5. (Level III)
32. Heinemann K, Reed S, Moehner S, Minh TD. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active SurveillanceStudyonIntrauterineDevices.Contraception 2015;91:274-9. (Level II-3)
33. ® (etonogestrel implant). Merck & Co., Inc: Whitehouse Station, (NJ); 2016. Available at: http://www.merck.com/product/usa/pi_circulars/i/implanon/implanon_pi.pdf. Retrieved December 6, 2016. (Level III)
34. ® (etonogestrel implant). Merck & Co., Inc.: Whitehouse Station (NJ); 2016. Available at: http://www.merck.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf. Retrieved December 6, 2016. (Level III)
35. Graesslin O, Korver T. The contraceptive efficacy of Implanon: a review of clinical trials and marketing experience. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:4-12. (Level III)
36. Davies GC, Feng LX, Newton JR, Van Beek A, Coelingh-Bennink HJ. Release characteristics, ovarian activity and menstrual bleeding pattern with a single contraceptive implant releasing 3-ketodesogestrel. Contraception 1993;47:251-61. (Level III)
37. Croxatto HB. Mechanisms that explain the contraceptive action of progestin implants for women. Contraception 2002;65:21-7. (Level III)
38. Van den Bosch T, Donders GG, Riphagen I, Debois P, Ameye L, De Brabanter J, et al. Ultrasonographic features of the endometrium and the ovaries in women on etonogestrel implant. Ultrasound Obstet Gynecol 2002;20:377-80. (Level II-3)
39. Xu H, Wade JA, Peipert JF, Zhao Q, Madden T, Secura GM. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol 2012;120:21-6. (Level II-2)
40. Zheng SR, Zheng HM, Qian SZ, Sang GW, Kaper RF. A randomized multicenter study comparing the efficacy and bleeding pattern of a single-rod (Implanon) and a six-capsule (Norplant) hormonal contraceptive implant. Contraception 1999;60:1-8. (Level I)
41. Blumenthal PD, Gemzell-Danielsson K, Marintcheva-Petrova M. Tolerability and clinical safety of Implanon. Eur J Contracept Reprod Health Care 2008;13(suppl 1): 29-36. (Level II-3)
42. Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. Fertil Steril 2009;91:1646-53. (Level II-3)
43. Modesto W, Bahamondes MV, Bahamondes L. A randomized clinical trial of the effect of intensive versus non-intensive counselling on discontinuation rates due to bleeding disturbances of three long-acting reversible contraceptives. Hum Reprod 2014;29:1393-9. (Level I)
44. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Implanon US Study Group. Contraception 2005;71:319-26. (Level II-3)
45. Modesto W, Dal Ava N, Monteiro I, Bahamondes L. Body composition and bone mineral density in users of the etonogestrel-releasing contraceptive implant. Arch Gynecol Obstet 2015;292:1387-91. (Level II-3)
46. Beerthuizen R, van Beek A, Massai R, Makarainen L, Hout J, Bennink HC. Bone mineral density during long-term use of the progestagen contraceptive implant Implanon compared to a non-hormonal method of contraception. Hum Reprod 2000;15:118-22. (Level II-2)
47. Curtis KM, Tepper NK, Jatlaoui TC, Berry-Bibee E, Horton LG, Zapata LB, et al. U.S. medical eligibility criteria for contraceptive use, 2016. MMWR Recomm Rep 2016;65(RR-3):1-103. (Level III)
48. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. U.S. selected practice recommendations for contraceptive use, 2016. MMWR Recomm Rep 2016;65(RR-4):1-66. (Level III)
49. Adolescents and long-acting reversible contraception: implants and intrauterine devices. Committee Opinion No. 539. American College of Obstetricians and Gynecologists. Obstet Gynecol 2012;120:983-8. (Level III)
50. Contraception for adolescents. Committee on Adolescence. Pediatrics 2014;134:e1244-56. (Level III)
51. Mestad R, Secura G, Allsworth JE, Madden T, Zhao Q, Peipert JF. Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project. Contraception 2011;84:493-8. (Level III)
52. Abraham M, Zhao Q, Peipert JF. Young age, nulliparity, and continuation of long-acting reversible contraceptive methods. Obstet Gynecol 2015;126:823-9. (Level II-3)
53. Tyler CP, Whiteman MK, Zapata LB, Curtis KM, Hillis SD, Marchbanks PA. Health care provider attitudes and practices related to intrauterine devices for nulliparous women. Obstet Gynecol 2012;119:762-71. (Level III)
54. Madden T, Allsworth JE, Hladky KJ, Secura GM, Peipert JF. Intrauterine contraception in Saint Louis: a survey of obstetrician and gynecologists' knowledge and attitudes. Contraception 2010;81:112-6. (Level III)
55. Luchowski AT, Anderson BL, Power ML, Raglan GB, Espey E, Schulkin J. Obstetrician-gynecologists and contraception: practice and opinions about the use of IUDs in nulliparous women, adolescents and other patient populations. Contraception 2014;89:572-7. (Level III)
56. Aoun J, Dines VA, Stovall DW, Mete M, Nelson CB, Gomez-Lobo V. Effects of age, parity, and device type on complications and discontinuation of intrauterine devices. Obstet Gynecol 2014;123:585-92. (Level II-3)
57. Berenson AB, Tan A, Hirth JM, Wilkinson GS. Complications and continuation of intrauterine device use among commercially insured teenagers. Obstet Gynecol 2013;121:951-8. (Level II-2)
58. Teal SB, Romer SE, Goldthwaite LM, Peters MG, Kaplan DW, Sheeder J. Insertion characteristics of intrauterine devices in adolescents and young women: success, ancillary measures, and complications. Am J Obstet Gynecol 2015;213:515.e1-5. (Level II-3)
59. Deans EI, Grimes DA. Intrauterine devices for adolescents: a systematic review. Contraception 2009;79: 418-23. (Systematic Review)
60. Madden T, McNicholas C, Zhao Q, Secura GM, Eisenberg DL, Peipert JF. Association of age and parity with intrauterine device expulsion. Obstet Gynecol 2014;124:718-26. (Level II-3)
61. McNicholas C, Madden T, Secura G, Peipert JF. The contraceptive CHOICE project round up: what we did and what we learned. Clin Obstet Gynecol 2014;57: 635-43. (Level III)
62. Steenland MW, Zapata LB, Brahmi D, Marchbanks PA, Curtis KM. Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review. Contraception 2013;87: 611-24. (Systematic Review)
63. Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. N Engl J Med 2001;345:561-7. (Level II-2)
64. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010;81:421-6. (Level II-3)
65. Obijuru L, Bumpus S, Auinger P, Baldwin CD. Etonogestrel implants in adolescents: experience, satisfaction, and continuation. J Adolesc Health 2016;58: 284-9. (Level III)
66. Whiteman MK, Tyler CP, Folger SG, Gaffield ME, Curtis KM. When can a woman have an intrauterine device inserted? A systematic review. Contraception 2013;87:666-73. (Systematic Review)
67. Access to contraception. Committee Opinion No. 615. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;125:250-5. (Level III)
68. Bergin A, Tristan S, Terplan M, Gilliam ML, Whitaker AK. A missed opportunity for care: two-visit IUD insertion protocols inhibit placement. Contraception 2012;86:694-7. (Level II-3)
69. Lahteenmaki P, Luukkainen T. Return of ovarian function after abortion. Clin Endocrinol (Oxf) 1978;8:123-32. (Level III)
70. Fox MC, Oat-Judge J, Severson K, Jamshidi RM, Singh RH, McDonald-Mosley R, et al. Immediate placement of intrauterine devices after first and second trimester pregnancy termination. Contraception 2011;83:34-40. (Level II-2)
71. Goodman S, Hendlish SK, Reeves MF, Foster-Rosales A. Impact of immediate postabortal insertion of intrauterine contraception on repeat abortion. Contraception 2008;78:143-8. (Level II-2)
72. Madden T, Secura GM, Allsworth JE, Peipert JF. Comparison of contraceptive method chosen by women with and without a recent history of induced abortion. Contraception 2011;84:571-7. (Level II-3)
73. Steenland MW, Tepper NK, Curtis KM, Kapp N. Intrauterine contraceptive insertion postabortion: a systematic review. Contraception 2011;84:447-64. (Systematic Review)
74. Bednarek PH, Creinin MD, Reeves MF, Cwiak C, Espey E, Jensen JT. Immediate versus delayed IUD insertion after uterine aspiration. Post-Aspiration IUD Randomization (PAIR) Study Trial Group. N Engl J Med 2011;364:2208-17. (Level I)
75. Betstadt SJ, Turok DK, Kapp N, Feng KT, Borgatta L. Intrauterine device insertion after medical abortion. Contraception 2011;83:517-21. (Level II-2)
76. Shimoni N, Davis A, Ramos ME, Rosario L, Westhoff C. Timing of copper intrauterine device insertion after medical abortion: a randomized controlled trial. Obstet Gynecol 2011;118:623-8. (Level I)
77. Raymond EG, Weaver MA, Tan YL, Louie KS, Bousieguez M, Lugo-Hernandez EM, et al. Effect of immediate compared with delayed insertion of etonogestrel implants on medical abortion efficacy and repeat pregnancy: a randomized controlled trial. Obstet Gynecol 2016;127:306-12. (Level I)
78. Mark A, Sonalkar S, Borgatta L. One-year continuation of the etonogestrel contraceptive implant in women with postabortion or interval placement. Contraception 2013;88:619-23. (Level II-3)
79. Madden T, Eisenberg DL, Zhao Q, Buckel C, Secura GM, Peipert JF. Continuation of the etonogestrel implant in women undergoing immediate postabortion placement. Obstet Gynecol 2012;120:1053-9. (Level II-2)
80. Increasing access to contraceptive implants and intrauterine devices to reduce unintended pregnancy. Committee Opinion No. 642. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015; 126:e44-8. (Level III)
81. Immediate postpartum long-acting reversible contraception. Committee Opinion No. 670. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e32-7. (Level III)
82. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011;117:657-62. (Systematic Review)
83. McDonald EA, Brown SJ. Does method of birth make a difference to when women resume sex after childbirth? BJOG 2013;120:823-30. (Level II-3)
84. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sa MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519-26. (Level I)
85. Connolly A, Thorp J, Pahel L. Effects of pregnancy and childbirth on postpartum sexual function: a longitudinal prospective study. Int Urogynecol J Pelvic Floor Dysfunct 2005;16:263-7. (Level II-3)
86. Washington CI, Jamshidi R, Thung SF, Nayeri UA, Caughey AB, Werner EF. Timing of postpartum intrauterine device placement: a cost-effectiveness analysis. Fertil Steril 2015;103:131-7. (Cost-benefit)
87. Chen BA, Reeves MF, Hayes JL, Hohmann HL, Perriera LK, Creinin MD. Postplacental or delayed insertion of the levonorgestrel intrauterine device after vaginal delivery: a randomized controlled trial. Obstet Gynecol 2010;116:1079-87. (Level I)
88. Dahlke JD, Terpstra ER, Ramseyer AM, Busch JM, Rieg T, Magann EF. Postpartum insertion of levonorgestrel-intrauterine system at three time periods: a prospective randomized pilot study. Contraception 2011;84:244-8. (Level I)
89. Hayes JL, Cwiak C, Goedken P, Zieman M. A pilot clinical trial of ultrasound-guided postplacental insertion of a levonorgestrel intrauterine device. Contraception 2007;76:292-6. (Level III)
90. Celen S, Sucak A, Yildiz Y, Danisman N. Immediate postplacental insertion of an intrauterine contraceptive device during cesarean section. Contraception 2011; 84:240-3. (Level II-3)
91. Ogburn JA, Espey E, Stonehocker J. Barriers to intrauterine device insertion in postpartum women. Contraception 2005;72:426-9. (Level III)
92. Levi EE, Stuart GS, Zerden ML, Garrett JM, Bryant AG. Intrauterine device placement during cesarean delivery and continued use 6 months postpartum: a randomized controlled trial. Obstet Gynecol 2015;126:5-11. (Level I)
93. Phillips SJ, Tepper NK, Kapp N, Nanda K, Temmerman M, Curtis KM. Progestogen-only contraceptive use among breastfeeding women: a systematic review. Contraception 2016;94:226-52. (Systematic Review)
94. Shaamash AH, Sayed GH, Hussien MM, Shaaban MM. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development. Contraception 2005;72:346-51. (Level I)
95. Braga GC, Ferriolli E, Quintana SM, Ferriani RA, Pfrimer K, Vieira CS. Immediate postpartum initiation of etonogestrel-releasing implant: A randomized controlled trial on breastfeeding impact. Contraception 2015;92:536-42. (Level I)
96. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol 2011;117:1114-21. (Level I)
97. Reinprayoon D, Taneepanichskul S, Bunyavejchevin S, Thaithumyanon P, Punnahitananda S, Tosukhowong P, et al. Effects of the etonogestrel-releasing contraceptive implant (Implanon on parameters of breastfeeding compared to those of an intrauterine device. Contraception 2000;62:239-46. (Level II-3)
98. Taneepanichskul S, Reinprayoon D, Thaithumyanon P, Praisuwanna P, Tosukhowong P, Dieben T. Effects of the etonogestrel-releasing implant Implanon and a non-medicated intrauterine device on the growth of breast-fed infants. Contraception 2006;73:368-71. (Level II-3)
99. Optimizing support for breastfeeding as part of obstetric practice. Committee Opinion No. 658. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e86-92. (Level III)
100. Cheng L, Che Y, Gülmezoglu AM. Interventions for emergency contraception. Cochrane Database of Systematic Reviews 2012, Issue 8. Art. No.: CD001324. DOI: 10. 1002/14651858.CD001324.pub4. (Meta-Analysis)
101. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience. Hum Reprod 2012;27:1994-2000. (Systematic Review)
102. Emergency contraception. Practice Bulletin No. 152. American College of Obstetricians and Gynecologists. Obstet Gynecol 2015;126:e1-11. (Level III)
103. Moreau C, Trussell J. Results from pooled Phase III studies of ulipristal acetate for emergency contraception. Contraception 2012;86:673-80. (Level III)
104. Kapp N, Abitbol JL, Mathe H, Scherrer B, Guillard H, Gainer E, et al. Effect of body weight and BMI on the efficacy of levonorgestrel emergency contraception. Contraception 2015;91:97-104. (Level II-3)
105. Glasier A, Cameron ST, Blithe D, Scherrer B, Mathe H, Levy D, et al. Can we identify women at risk of pregnancy despite using emergency contraception? Data from randomized trials of ulipristal acetate and levonorgestrel. Contraception 2011;84:363-7. (Level III)
106. Grimes DA, Shields WC. Family planning for obese women: challenges and opportunities. Contraception 2005;72:1-4. (Level III)
107. Wu S, Godfrey EM, Wojdyla D, Dong J, Cong J, Wang C, et al. Copper T380A intrauterine device for emergency contraception: a prospective, multicentre, cohort clinical trial. BJOG 2010;117:1205-10. (Level II-2)
108. Turok DK, Jacobson JC, Dermish AI, Simonsen SE, Gurtcheff S, McFadden M, et al. Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates. Contraception 2014;89:222-8. (Level II-3)
109. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception 2014;89:495-503. (Level III)
110. McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration. Am J Obstet Gynecol 2017;216:586.e1-586.e6. (Level II-2)
111. Rowe P, Farley T, Peregoudov A, Piaggio G, Boccard S, Landoulsi S, et al. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A. IUD Research Group of the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. Contraception 2016;93:498-506. (Level I)
112. ® 52-mg intrauterine system. Contraception 2016;94:353-6. (Level II-3)
113. Ali M, Akin A, Bahamondes L, Brache V, Habib N, Landoulsi S, et al. Extended use up to 5 years of the etonogestrel-releasing subdermal contraceptive implant: comparison to levonorgestrel-releasing subdermal implant. WHO study group on subdermal contraceptive implants for women. Hum Reprod 2016;31:2491-8. (Level I)
114. Grentzer JM, Peipert JF, Zhao Q, McNicholas C, Secura GM, Madden T. Risk-based screening for Chlamydia trachomatis and Neisseria gonorrhoeae prior to intrauterine device insertion. Contraception 2015;92:313-8. (Level II-3)
115. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. Centers for Disease Control and Prevention [published erratum appears in MMWR Recomm Rep 2015;64:924]. MMWR Recomm Rep 2015;64(RR-03):1-137. (Level III)
116. Sufrin CB, Postlethwaite D, Armstrong MA, Merchant M, Wendt JM, Steinauer JE. Neisseria gonorrhea and Chlamydia trachomatis screening at intrauterine device insertion and pelvic inflammatory disease. Obstet Gynecol 2012;120:1314-21. (Level II-3)
117. Eisenberg DL, Allsworth JE, Zhao Q, Peipert JF. Correlates of dual-method contraceptive use: an analysis of the National Survey of Family Growth (2006-2008). Infect Dis Obstet Gynecol 2012;2012:717163. (Level II-3)
118. Mohllajee AP, Curtis KM, Peterson HB. Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review. Contraception 2006;73:145-53. (Systematic Review)
119. Birgisson NE, Zhao Q, Secura GM, Madden T, Peipert JF. Positive testing for Neisseria gonorrhoeae and chlamydia trachomatis and the risk of pelvic inflammatory disease in IUD users. J Womens Health (Larchmt) 2015;24:354-9. (Level II-3)
120. Ladipo OA, Farr G, Otolorin E, Konje JC, Sturgen K, Cox P, et al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Adv Contracept 1991;7:43-54. (Level I)
121. Sinei SK, Schulz KF, Lamptey PR, Grimes DA, Mati JK, Rosenthal SM, et al. Preventing IUCD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990;97:412-9. (Level I)
122. Antibiotic prophylaxis for gynecologic procedures. ACOG Practice Bulletin No. 104. American College of Obstetricians and Gynecologists. Obstet Gynecol 2009;113:1180-9. (Level III)
123. Grimes DA, Lopez LM, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Systematic Reviews 1999, Issue 3. Art. No.: CD001327. DOI: 10.1002/14651858. CD001327. (Systematic Review)
124. Farley TM, Rosenberg MJ, Rowe PJ, Chen JH, Meirik O. Intrauterine devices and pelvic inflammatory disease: an international perspective. Lancet 1992;339:785-8. (Level I)
125. Turok DK, Eisenberg DL, Teal SB, Keder LM, Creinin MD. A prospective assessment of pelvic infection risk following same-day sexually transmitted infection testing and levonorgestrel intrauterine system placement. Am J Obstet Gynecol 2016;215:599.e1-6. (Level II-3)
126. Backman T, Huhtala S, Luoto R, Tuominen J, Rauramo I, Koskenvuo M. Advance information improves user satisfaction with the levonorgestrel intrauterine system. Obstet Gynecol 2002;99:608-13. (Level II-3)
127. Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial. Contraception 1994;49:56-72. (Level I)
128. Grimes DA, Hubacher D, Lopez LM, Schulz KF. Nonsteroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006034. (Systematic Review)
129. Hubacher D, Chen PL, Park S. Side effects from the copper IUD: do they decrease over time? Contraception 2009;79:356-62. (Level II-3)
130. Heikinheimo O, Inki P, Schmelter T, Gemzell-Danielsson K. Bleeding pattern and user satisfaction in second consecutive levonorgestrel-releasing intrauterine system users: results of a prospective 5-year study. Hum Reprod 2014;29:1182-8. (Level II-3)
131. Madden T, Proehl S, Allsworth JE, Secura GM, Peipert JF. Naproxen or estradiol for bleeding and spotting with the levonorgestrel intrauterine system: a randomized controlled trial. Am J Obstet Gynecol 2012;206:129. e1-8. (Level I)
132. Sordal T, Inki P, Draeby J, O'Flynn M, Schmelter T. Management of initial bleeding or spotting after levonorgestrel-releasing intrauterine system placement: a randomized controlled trial. Obstet Gynecol 2013; 121:934-41. (Level I)
133. Varma R, Sinha D, Gupta JK. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)-a systematic enquiry and overview. Eur J Obstet Gynecol Reprod Biol 2006;125:9-28. (Systematic Review)
134. Jensen J, Mansour D, Lukkari-Lax E, Inki P, Burock K, Fraser IS. Bleeding patterns with the levonorgestrel-releasing intrauterine system when used for heavy menstrual bleeding in women without structural pelvic pathology: a pooled analysis of randomized controlled studies. Contraception 2013;87:107-12. (Level III)
135. Lethaby A, Hussain M, Rishworth JR, Rees MC. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database of Systematic Reviews 2015, Issue 4. Art. No.: CD002126. DOI: 10.1002/14651858.CD002126.pub3. (Systematic Review)
136. Gupta J, Kai J, Middleton L, Pattison H, Gray R, Daniels J. Levonorgestrel intrauterine system versus medical therapy for menorrhagia. ECLIPSE Trial Collaborative Group. N Engl J Med 2013;368:128-37. (Level I)
137. Mansour D, Korver T, Marintcheva-Petrova M, Fraser IS. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:13-28. (Level III)
138. Walch K, Unfried G, Huber J, Kurz C, van Trotsenburg M, Pernicka E, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis-a pilot study. Contraception 2009;79:29-34. (Level I)
139. Ireland LD, Goyal V, Raker CA, Murray A, Allen RH. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding. Contraception 2014;90:253-8. (Level II-3)
140. Mansour D, Bahamondes L, Critchley H, Darney P, Fraser IS. The management of unacceptable bleeding patterns in etonogestrel-releasing contraceptive implant users. Contraception 2011;83:202-10. (Level III)
141. Guiahi M, McBride M, Sheeder J, Teal S. Short-term treatment of bothersome bleeding for etonogestrel implant users using a 14-day oral contraceptive pill regimen: a randomized controlled trial. Obstet Gynecol 2015;126:508-13. (Level I)
142. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, et al. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24: 1852-61. (Level I)
143. Ozalp S, Kabukcuoglu S, Tanir HM. Should endometrial hyperplasia be regarded as a reason for abnormal uterine bleeding in users of the intrauterine contraceptive device? Eur J Contracept Reprod Health Care 2003;8:17-20. (Level III)
144. Westhoff C. IUDs and colonization or infection with actinomyces. Contraception 2007;75:S48-50. (Level III)
145. Brahmi D, Steenland MW, Renner RM, Gaffield ME, Curtis KM. Pregnancy outcomes with an IUD in situ: a systematic review. Contraception 2012;85:131-9. (Systematic Review)
146. Ganer H, Levy A, Ohel I, Sheiner E. Pregnancy outcome in women with an intrauterine contraceptive device. Am J Obstet Gynecol 2009;201:381.e1-5. (Level II-3)
147. Backman T, Rauramo I, Huhtala S, Koskenvuo M. Pregnancy during the use of levonorgestrel intrauterine system. Am J Obstet Gynecol 2004;190:50-4. (Level II-3)
148. Xiong X, Buekens P, Wollast E. IUD use and the risk of ectopic pregnancy: a meta-analysis of case-control studies. Contraception 1995;52:23-34. (Meta-analysis)
149. Sivin I. Dose- and age-dependent ectopic pregnancy risks with intrauterine contraception. Obstet Gynecol 1991;78:291-8. (Level III)
150. Sivin I, Stern J. Health during prolonged use of levonorgestrel 20 micrograms/d and the copper TCu 380Ag intrauterine contraceptive devices: a multicenter study. International Committee for Contraception Research (ICCR). Fertil Steril 1994;61:70-7. (Level I)
151. Sitruk-Ware R. The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception 2007;75:S155-60. (Level III)